News | October 27, 2025
Sanofi's Q3 profit dips marginally as Dupixent sales top €4 billion
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
This strategic collaboration represents the third clinical trial under Senhwa’s five-year NCI-sponsored cancer research program
Late-breaking data presented at WCLC highlight significant and sustained improvements in overall survival, including more than doubling five-year survival rates compared to chemotherapy alone
He has successfully led the development of 15 approved drugs worldwide across various therapeutic areas over his more than 20-year career
Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype
Ordspono is Regeneron’s first approved bispecific antibody and will provide an off-the-shelf option that can be administered in the out-patient setting, with hope for complete remission
Subscribe To Our Newsletter & Stay Updated
